Supplementary materials: Cost–effectiveness and cost–benefit analysis of oliceridine in the treatment of acute pain

These are peer-reviewed supplementary tables for the article 'Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1. Estimated mean and median cost and length of stay (LOS) derived from the 2017 National Inpatient Sample-Healthcare Cost and Utilization Project (NIS-HCUP) dataset.Supplementary Table 2. Estimated cost weights for opioid-induced respiratory depression events by type of surgery (in 2017 US dollars).Supplementary Table 3. Health economic model cost weights for opioid-induced respiratory depression, vomiting, and somnolence inflated to 2020 US dollar costs.Supplementary Table 4. Base model estimates: Summary of impact of sensitivity analyses on the base model estimates.Supplementary Table 5. Oliceridine parameter values used in the Monte Carlo simulations (values for morphine parameters were similarly varied).Summary: Aim: Oliceridine, a new class of μ-opioid receptor agonist, is selective for G-protein signaling (analgesia) with limited recruitment of β-arrestin (associated with adverse outcomes) and may provide a cost-effective alternative versus conventional opioid morphine for postoperative pain. Patients & methods: Using a decision tree with a 24-h time horizon, we calculated costs for medication and management of three most common adverse events (AEs; oxygen saturation

本数据集为发表于《比较有效性研究杂志》的论文《奥利昔布在急性疼痛治疗中的成本效益分析及成本效益分析》的同行评审补充表格。补充表格1：基于2017年全国住院样本-医疗成本和利用率项目（NIS-HCUP）数据集，估算的平均值和中位数成本及住院时间（LOS）。补充表格2：按手术类型估算的阿片类药物引起的呼吸抑制事件成本权重（以2017年美元计）。补充表格3：阿片类药物引起的呼吸抑制、呕吐和嗜睡的健康经济学模型成本权重，调整为2020年美元成本。补充表格4：基础模型估计：敏感性分析对基础模型估计的影响总结。补充表格5：在蒙特卡洛模拟中使用的奥利昔布参数值（吗啡参数值也进行了类似的调整）。摘要：目的：奥利昔布，一种新型μ-阿片受体激动剂，对G蛋白信号传导（镇痛）具有选择性，对β-arrestin（与不良后果相关）的募集有限，可能为与传统阿片类药物吗啡相比，提供一种成本效益更高的术后疼痛治疗方法。患者与方法：使用24小时时间跨度的决策树，我们计算了药物及管理三种最常见不良事件（AEs；血氧饱和度...